Morgan Stanley CKD (6407.T): Strong Semiconductor-Related Recovery; Expect Sharp Earnings Improvement from F3 27
Summaries are public. PDF access requires an active membership; all members have the same access. Sign in
Morgan Stanley notes that CKD (6407.T) is currently experiencing a robust recovery driven by resurgent semiconductor demand, with expectations of a substantial earnings improvement beginning in the third quarter of fiscal year 2027. The report emphasizes that the ongoing semiconductor cycle upturn serves as the primary catalyst for this positive trajectory.
According to the analysis, CKD's semiconductor-related business is witnessing a strong rebound in demand, which should directly translate into enhanced financial performance. The firm expects this momentum to support significant profitability gains moving forward. Morgan Stanley expresses an optimistic outlook for the company, suggesting that the current stock price may not fully reflect the anticipated earnings recovery.
The research outlines a clear causal chain: as the broader semiconductor industry recovers, CKD's order volumes increase, driving operating leverage and significantly improving bottom-line results starting in fiscal year 2027. The analyst presentation includes detailed forward price-to-book ratio charts, new versus old financial forecasts, complete income statements, balance sheets, cash flow statements, and comprehensive segment information to substantiate the thesis. However, the report does not provide specific target prices, ratings, or defined verification time windows.
Key exhibits
Exhibit 1
Exhibit 2
Exhibit 3
Exhibit 4
Exhibit 5
Exhibit 6
